Medicine & healthcare

FDA Recalls 11K Bottles of High Blood Pressure Medications

Is this a critical patient safety alert or proof of the risks of outsourced drug manufacturing?

Published JUL 9

FDA Recalls 11K Bottles of High Blood Pressure Medications

Story

Above: A generic image of a medication box in a hospital in Stuttgart, Germany on Oct. 8, 2025. Image credit: Bernd Weißbrod/picture alliance/Getty Images

The Facts

The U.S. Food and Drug Administration (FDA) has initiated a recall of chlorthalidone tablets, which are used to treat high blood pressure. The FDA classified the chlorthalidone recall as a Class II recall on June 22, following its initiation on June 5. A Class II recall indicates that use of the product may cause temporary or medically reversible adverse health consequences, with the likelihood of serious harm considered remote.
Courier Post
Dallas Express
Inventia Healthcare Limited, based in India, voluntarily recalled approximately 11,460 bottles of Chlorthalidone Tablets USP, 25 mg, after the tablets failed dissolution specifications during quality testing. The affected tablets were distributed nationwide by Rising Pharma Holdings Inc. of East Brunswick, New Jersey.
NBC Chicago
FOX News
Failed dissolution specifications mean the tablets may not dissolve in the body at the intended rate, potentially reducing the amount of active ingredient released into the bloodstream. Patients are advised not to stop taking prescribed blood pressure medication without first consulting a health care professional.
Dallas Express
Prevention
Chlorthalidone is a prescription diuretic used to treat high blood pressure and reduce fluid retention linked to conditions such as heart failure, kidney disease and liver disease. The recalled tablets are 25 mg, sold in 100-count and 1,000-count bottles expiring in April 2027.
Courier Post
FOX News
Patients with affected bottles — identified by lot numbers RISA24001 or RISB24002 and NDC codes 64980-599-01 or 64980-599-10 — are advised to contact their pharmacist or health care provider. No consumer claim form is required, and pharmacies can typically replace an affected bottle at no cost.
Prevention
Open Class Actions
This comes amid several recent medication recalls in June, including enalapril maleate and Corlanor recalled as Class II actions, while more than 500,000 bottles of Prazosin Hydrochloride were recalled in October over concerns about unsafe levels of cancer-causing chemicals.
NBC Chicago
The Hill

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Pro-establishment narrative

Medication recalls like this are a reminder that quality control failures can have real consequences, especially for people relying on daily treatment to manage chronic conditions. Rather than assuming every prescription is unaffected, patients should stay alert to recall notices and speak with a pharmacist or health care provider before changing how they take their medication.

FOX News

Prevention

Establishment-critical narrative

This is the predictable result of a system that outsourced drug manufacturing to overseas factories with a documented history of contamination, fraud and destroyed safety records. The FDA has even quietly granted exemptions, allowing drugs from banned Indian factories to keep flowing to American patients. Recalls will only continue until manufacturing is brought back to the U.S.